{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:53:56Z","timestamp":1790819636013,"version":"4.1.0"},"reference-count":115,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Low back pain (LBP) is a highly prevalent musculoskeletal problem and a leading cause of disability worldwide. From a pathophysiological perspective, the contribution of inflammation to LBP is being increasingly recognized. In this literature review, we aim to provide an overview of the role of inflammation as a mediator of LBP while summarizing clinical studies investigating the potential role of anti-inflammatory treatments in the management of LBP. Although often controversial, the available evidence suggests an important role of inflammation in the pathogenesis of LBP, which can be further translated into novel therapeutic targets. Both anti-tumor necrosis factor (anti-TNF) and anti-nerve growth factor (anti-NGF) agents hold the potential of blocking inflammation and pain pathways in patients with chronic LBP. TNF inhibitors have been tested mostly in small trials with mixed results, and their long-term efficacy remains to be proven. Anti-NGF agents have demonstrated stronger and consistent efficacy in randomized controlled trials, but safety concerns compromise their widespread use. The potential role of other anti-inflammatory molecules is currently under investigation. Presently, the routine use of TNF or NGF inhibitors is not supported in radiculopathy or chronic LBP. However, novel anti-inflammatory therapies introduced in the rheumatology field appear to be promising for specific subsets of patients suffering from chronic, refractory LBP, with a complementary role as therapeutic tools, after the unsuccessful outcome of the conservative approach.<\/jats:p>","DOI":"10.3390\/ph18111612","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:50:48Z","timestamp":1761533448000},"page":"1612","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting Inflammatory Pathways in Chronic Low Back Pain: Opportunities for Novel Therapeutics"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-4629","authenticated-orcid":false,"given":"Panagiota","family":"Anyfanti","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-5111","authenticated-orcid":false,"given":"Paschalis","family":"Evangelidis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippo\u03baration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5764-1320","authenticated-orcid":false,"given":"Konstantinos","family":"Tragiannidis","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5164-7435","authenticated-orcid":false,"given":"Christina","family":"Antza","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Poulis","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-1642","authenticated-orcid":false,"given":"Theodoros","family":"Dimitroulas","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-8097","authenticated-orcid":false,"given":"Vasilios","family":"Kotsis","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"ref_1","unstructured":"(2023). GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990\u20132020, its attributable risk factors, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol., 5, e316\u2013e329."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00508-019-01542-7","article-title":"Association between low back pain and various everyday performances: Activities of daily living, ability to work and sexual function","volume":"131","author":"Grabovac","year":"2019","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.31138\/mjr.33.3.305","article-title":"The Relationship Between Fear-Avoidance Beliefs, Disability, and Physical Capacity in Patients with Chronic Low Back Pain","volume":"33","author":"Nazir","year":"2022","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.14245\/ns.2448372.186","article-title":"Comparative Review of the Socioeconomic Burden of Lower Back Pain in the United States and Globally","volume":"21","author":"Chang","year":"2024","journal-title":"Neurospine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/eurjpc\/zwac127","article-title":"The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank","volume":"29","author":"Ronnegard","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1186\/s12889-025-21904-3","article-title":"Association between a body shape index and low back pain: A cross-sectional study highlighting gender-specific differences in NHANES data","volume":"25","author":"Xie","year":"2025","journal-title":"BMC Public. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"E255","DOI":"10.36076\/ppj.2024.27.E255","article-title":"Chronic Low Back Pain and Sleep Disturbance in Adults in the US: The NHANES 2009-2010 Study","volume":"27","author":"Tong","year":"2024","journal-title":"Pain Physician"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbi.2016.10.003","article-title":"Systemic inflammatory profiles and their relationships with demographic, behavioural and clinical features in acute low back pain","volume":"60","author":"Klyne","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Reynolds, C.A., and Minic, Z. (2023). Chronic Pain-Associated Cardiovascular Disease: The Role of Sympathetic Nerve Activity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065378"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e54309","DOI":"10.1371\/journal.pone.0054309","article-title":"Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients--a nationwide study","volume":"8","author":"Olsen","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CRD.0b013e31821ddcf4","article-title":"The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients","volume":"19","author":"Snowden","year":"2011","journal-title":"Cardiol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/BRS.0b013e31815e7f94","article-title":"A consensus approach toward the standardization of back pain definitions for use in prevalence studies","volume":"33","author":"Dionne","year":"2008","journal-title":"Spine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.mcna.2014.03.005","article-title":"Acute and chronic low back pain","volume":"98","author":"Patrick","year":"2014","journal-title":"Med. Clin. N. Am."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11916-019-0757-1","article-title":"Low Back Pain, a Comprehensive Review: Pathophysiology, Diagnosis, and Treatment","volume":"23","author":"Urits","year":"2019","journal-title":"Curr. Pain. Headache Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70021","DOI":"10.1002\/jsp2.70021","article-title":"Contemporary clinical perspectives on chronic low back pain: The biology, mechanics, etc. underpinning clinical and radiological evaluation","volume":"8","author":"Sima","year":"2025","journal-title":"JOR Spine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/M19-3602","article-title":"Nonpharmacologic and Pharmacologic Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries in Adults: A Clinical Guideline From the American College of Physicians and American Academy of Family Physicians","volume":"173","author":"Qaseem","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"h444","DOI":"10.1136\/bmj.h444","article-title":"Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: Cochrane systematic review and meta-analysis","volume":"350","author":"Kamper","year":"2015","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1212\/WNL.0b013e3182872e80","article-title":"Pain assessment using the NIH Toolbox","volume":"80","author":"Cook","year":"2013","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.spinee.2018.05.018","article-title":"Risk factors for low back pain and sciatica: An umbrella review","volume":"18","author":"Parreira","year":"2018","journal-title":"Spine J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.31138\/mjr.33.3.291","article-title":"Stop Searching under the Streetlight! A Primer and Practical Guide to the Diagnosis of Joint Pain and Inflammation","volume":"33","author":"Krasin","year":"2022","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/pm\/pny214","article-title":"Biologic Drugs as Analgesics for the Management of Low Back Pain and Sciatica","volume":"20","author":"Dimitroulas","year":"2019","journal-title":"Pain. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/ar2275","article-title":"Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile","volume":"9","author":"Hoyland","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1097\/00007632-200012010-00003","article-title":"2000 Volvo Award winner in basic science studies: Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology. Molecular, histologic, and behavioral comparisons in rats","volume":"25","author":"Igarashi","year":"2000","journal-title":"Spine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/00007632-200104150-00007","article-title":"Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: Possible implications for future pharmacologic treatment strategies of sciatica","volume":"26","author":"Olmarker","year":"2001","journal-title":"Spine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.wneu.2021.09.066","article-title":"Fundamentals of Intervertebral Disc Degeneration","volume":"157","author":"Kirnaz","year":"2022","journal-title":"World Neurosurg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s00586-009-1092-8","article-title":"Nucleus pulposus tissue engineering: A brief review","volume":"18","author":"Yang","year":"2009","journal-title":"Eur. Spine J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/03008207.2023.2212051","article-title":"Contribution of immune cells to intervertebral disc degeneration and the potential of immunotherapy","volume":"64","author":"Xu","year":"2023","journal-title":"Connect. Tissue Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41540-024-00479-6","article-title":"Nucleus pulposus cell network modelling in the intervertebral disc","volume":"11","author":"Tseranidou","year":"2025","journal-title":"NPJ Syst. Biol. Appl."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mohd Isa, I.L., Teoh, S.L., Mohd Nor, N.H., and Mokhtar, S.A. (2022). Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010208"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cazzanelli, P., and Wuertz-Kozak, K. (2020). MicroRNAs in Intervertebral Disc Degeneration, Apoptosis, Inflammation, and Mechanobiology. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103601"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12026-025-09667-w","article-title":"Molecular mechanisms and treatment strategies for discogenic lumbar pain","volume":"73","author":"Yan","year":"2025","journal-title":"Immunol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70011","DOI":"10.1002\/jsp2.70011","article-title":"Targeting nucleus pulposus cell death in the treatment of intervertebral disc degeneration","volume":"7","author":"Sun","year":"2024","journal-title":"JOR Spine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/art.22985","article-title":"High-sensitivity C-reactive protein in chronic low back pain with vertebral end-plate Modic signal changes","volume":"57","author":"Rannou","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ejpain.2005.11.005","article-title":"The course of high-sensitive C-reactive protein in correlation with pain and clinical function in patients with acute lumbosciatic pain and chronic low back pain\u2014A 6 months prospective longitudinal study","volume":"10","author":"Gebhardt","year":"2006","journal-title":"Eur. J. Pain."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1342","DOI":"10.31661\/gmj.v9i0.1342","article-title":"Association of Serum Minerals, Vitamin D, Total Protein, and Inflammatory Mediators and Severity of Low Back Pain","volume":"9","author":"Dadkhah","year":"2020","journal-title":"Galen. Med. J."},{"key":"ref_38","unstructured":"Singh, B., Goyal, A., and Patel, B.C. (2025). C-Reactive Protein: Clinical Relevance and Interpretation. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1515\/sjpain-2019-0033","article-title":"The association between insomnia, c-reactive protein, and chronic low back pain: Cross-sectional analysis of the HUNT study, Norway","volume":"19","author":"Ho","year":"2019","journal-title":"Scand. J. Pain"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.sleep.2022.11.013","article-title":"Associations among acute and chronic musculoskeletal pain, sleep duration, and C-reactive protein (CRP): A cross-sectional study of the UK biobank dataset","volume":"101","author":"Hodges","year":"2023","journal-title":"Sleep Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1590\/S1516-31802010000500003","article-title":"Serum cytokine levels in patients with chronic low back pain due to herniated disc: Analytical cross-sectional study","volume":"128","author":"Kraychete","year":"2010","journal-title":"Sao Paulo Med. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00361","DOI":"10.1042\/BSR20160187","article-title":"Inflammation in low back pain may be detected from the peripheral blood: Suggestions for biomarker","volume":"36","author":"Li","year":"2016","journal-title":"Biosci. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbi.2015.01.008","article-title":"Serum levels of the pro-inflammatory interleukins 6 (IL-6) and -8 (IL-8) in patients with lumbar radicular pain due to disc herniation: A 12-month prospective study","volume":"46","author":"Pedersen","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12974-016-0565-z","article-title":"Differential expression of P2X7 receptor and IL-1beta in nociceptive and neuropathic pain","volume":"13","author":"Luchting","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10953","DOI":"10.3390\/molecules180910953","article-title":"Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain","volume":"18","author":"Alves","year":"2013","journal-title":"Molecules"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/AJP.0000000000000745","article-title":"Nonspecific Low Back Pain: Inflammatory Profiles of Patients with Acute and Chronic Pain","volume":"35","author":"Triano","year":"2019","journal-title":"Clin. J. Pain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/AJP.0000000000000507","article-title":"Elevated Production of Nociceptive CC Chemokines and sE-Selectin in Patients with Low Back Pain and the Effects of Spinal Manipulation: A Nonrandomized Clinical Trial","volume":"34","author":"McGregor","year":"2018","journal-title":"Clin. J. Pain"},{"key":"ref_48","first-page":"E1015","article-title":"Relationship between Vitamin D and Nonspecific Low Back Pain May Be Mediated by Inflammatory Markers","volume":"24","author":"Xu","year":"2021","journal-title":"Pain Physician"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.reuma.2022.07.002","article-title":"Pro-inflammatory cytokines in patients with low back pain: A comparative study","volume":"19","author":"Slouma","year":"2023","journal-title":"Reumatol. Clin."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e001726","DOI":"10.1136\/rmdopen-2021-001726","article-title":"Macrophage migration inhibitory factor: A potential biomarker for chronic low back pain in patients with Modic changes","volume":"7","author":"Gjefsen","year":"2021","journal-title":"RMD Open"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/AJP.0b013e3181eef761","article-title":"Chronic low back pain, sleep disturbance, and interleukin-6","volume":"27","author":"Heffner","year":"2011","journal-title":"Clin. J. Pain"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2147\/JPR.S153872","article-title":"Unexpectedly decreased plasma cytokines in patients with chronic back pain","volume":"11","author":"Capossela","year":"2018","journal-title":"J. Pain Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Stec-Martyna, E., Wojtczak, K., Nowak, D., and Stawski, R. (2025). Battle of the Biomarkers of Systemic Inflammation. Biology, 14.","DOI":"10.3390\/biology14040438"},{"key":"ref_54","first-page":"CD009790","article-title":"Exercise therapy for chronic low back pain","volume":"9","author":"Hayden","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e607","DOI":"10.1016\/S2665-9913(25)00064-5","article-title":"Long-term effectiveness of non-surgical interventions for chronic low back pain: A systematic review and meta-analysis","volume":"7","author":"Jenkins","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"ref_56","first-page":"233","article-title":"Chronic Low Back Pain in Adults: Evaluation and Management","volume":"109","author":"Maharty","year":"2024","journal-title":"Am. Fam. Physician"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-2094-7-27","article-title":"TNF-\u03b1 and neuropathic pain\u2014A review","volume":"7","author":"Leung","year":"2010","journal-title":"J. Neuroinflamm."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Udalova, I., Monaco, C., Nanchahal, J., and Feldmann, M. (2016). Anti-TNF Therapy. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.MCHD-0022-2015"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Leone, G.M., Mangano, K., Petralia, M.C., Nicoletti, F., and Fagone, P. (2023). Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041630"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents\u2014Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"ref_61","first-page":"e37672","article-title":"Recent Advancements in Epidural Etanercept for Pain Management in Radiculopathy: A Literature Review","volume":"15","author":"Joseph","year":"2023","journal-title":"Cureus"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/art.43073","article-title":"Efficacy of a Tumor Necrosis Factor Inhibitor in Chronic Low-Back Pain with Modic Type 1 Changes: A Randomized Controlled Trial","volume":"77","author":"Gjefsen","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/BRS.0000000000005391","article-title":"Modic Change Edema in Chronic Low Back Pain Treated with Infliximab or Placebo: The BackToBasic Trial","volume":"50","author":"Dagestad","year":"2025","journal-title":"Spine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jbspin.2019.01.024","article-title":"Exploratory study of adalimumab in twelve patients with chronic low back pain associated with Modic I changes","volume":"86","author":"Genevay","year":"2019","journal-title":"Joint Bone Spine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40259-017-0217-6","article-title":"Golimumab: A Review in Inflammatory Arthritis","volume":"31","author":"Frampton","year":"2017","journal-title":"BioDrugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40259-016-0197-y","article-title":"Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases","volume":"30","author":"Deeks","year":"2016","journal-title":"BioDrugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14712598.2017.1283401","article-title":"Certolizumab pegol for the treatment of psoriasis","volume":"17","author":"Campanati","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-018-0971-x","article-title":"Beyond the TNF-alpha Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology","volume":"78","author":"Pedersen","year":"2018","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"551","DOI":"10.7326\/0003-4819-156-8-201204170-00397","article-title":"Epidural steroids, etanercept, or saline in subacute sciatica: A multicenter, randomized trial","volume":"156","author":"Cohen","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/art.27499","article-title":"Adalimumab in severe and acute sciatica: A multicenter, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Genevay","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/BSD.0b013e31819afdc4","article-title":"Tumor necrosis alpha-blocking agent (etanercept): A triple blind randomized controlled trial of its use in treatment of sciatica","volume":"23","author":"Okoro","year":"2010","journal-title":"J. Spinal Disord. Tech."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/ALN.0b013e3181a05aa0","article-title":"Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica","volume":"110","author":"Cohen","year":"2009","journal-title":"Anesthesiology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.anes.0000267518.20363.0d","article-title":"A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy","volume":"107","author":"Cohen","year":"2007","journal-title":"Anesthesiology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1097\/01.brs.0000190815.13764.64","article-title":"The treatment of disc herniation-induced sciatica with infliximab: Results of a randomized, controlled, 3-month follow-up study","volume":"30","author":"Korhonen","year":"2005","journal-title":"Spine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2011-200373","article-title":"Adalimumab in acute sciatica reduces the long-term need for surgery: A 3-year follow-up of a randomised double-blind placebo-controlled trial","volume":"71","author":"Genevay","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/BRS.0b013e318238af83","article-title":"Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: A prospective randomized study","volume":"37","author":"Ohtori","year":"2012","journal-title":"Spine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/1570159X16666180412092859","article-title":"Nerve Growth Factor: Early Studies and Recent Clinical Trials","volume":"16","author":"Rocco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/papr.12342","article-title":"NGF\/TrkA Signaling as a Therapeutic Target for Pain","volume":"16","author":"Hirose","year":"2016","journal-title":"Pain Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11926-012-0289-8","article-title":"Control of arthritis pain with anti-nerve-growth factor: Risk and benefit","volume":"14","author":"Seidel","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/08820538.2023.2168485","article-title":"Can Nerve Growth Factor (NGF) Be a Treatment Option for Pediatric Eye Diseases?","volume":"38","author":"Fulton","year":"2023","journal-title":"Semin. Ophthalmol."},{"key":"ref_81","first-page":"283","article-title":"Clinical applications of NGF in ocular diseases","volume":"149","author":"Lambiase","year":"2011","journal-title":"Arch. Ital. Biol."},{"key":"ref_82","first-page":"25","article-title":"Synovial and serum levels of NGF in osteoarthritis and rheumatic diseases: A systematic review","volume":"34","author":"Baldini","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2131\/jts.43.1","article-title":"Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues","volume":"43","author":"Belanger","year":"2018","journal-title":"J. Toxicol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nbt0412-298a","article-title":"Anti-nerve growth factor drugs exonerated","volume":"30","author":"Carey","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40265-014-0208-6","article-title":"Targeting nerve growth factor (NGF) for pain management: What does the future hold for NGF antagonists?","volume":"74","author":"Bannwarth","year":"2014","journal-title":"Drugs"},{"key":"ref_86","first-page":"e46790","article-title":"Various Doses of Tanezumab in the Management of Chronic Low Back Pain (CLBP): A Pooled Analysis of 4,514 Patients","volume":"15","author":"Tahir","year":"2023","journal-title":"Cureus"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2217\/pmt-2021-0040","article-title":"Tanezumab for chronic low back pain: A long-term, randomized, celecoxib-controlled Japanese Phase III safety study","volume":"12","author":"Konno","year":"2022","journal-title":"Pain. Manag."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/WNF.0000000000000530","article-title":"Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain: A Meta-analysis of Randomized Controlled Trials","volume":"46","author":"Lian","year":"2023","journal-title":"Clin. Neuropharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s40265-017-0781-6","article-title":"Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?","volume":"77","author":"Bannwarth","year":"2017","journal-title":"Drugs"},{"key":"ref_90","first-page":"E45","article-title":"Anti-nerve growth factor in the treatment of low back pain and radiculopathy: A systematic review and a meta-analysis","volume":"17","author":"Leite","year":"2014","journal-title":"Pain Physician"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s10067-024-07292-w","article-title":"Standardized efficacy and safety evaluation of fulranumab for osteoarthritis","volume":"44","author":"Kou","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.39943","article-title":"Long-Term Safety and Efficacy of Fulranumab in Patients with Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study","volume":"69","author":"Sanga","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.clinthera.2016.03.030","article-title":"Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients with Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study","volume":"38","author":"Sanga","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/annrheumdis-2020-217259","article-title":"Efficacy and safety of fasinumab in patients with chronic low back pain: A phase II\/III randomised clinical trial","volume":"80","author":"Dakin","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.pain.2011.05.003","article-title":"Efficacy and safety of tanezumab in the treatment of chronic low back pain","volume":"152","author":"Katz","year":"2011","journal-title":"Pain"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.joca.2014.08.014","article-title":"Imaging atlas for eligibility and on-study safety of potential joint adverse events in anti-NGF studies","volume":"23","author":"Roemer","year":"2015","journal-title":"Osteoarthr. Cartil."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.pain.2013.03.006","article-title":"Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain","volume":"154","author":"Kivitz","year":"2013","journal-title":"Pain"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.pain.2014.06.004","article-title":"Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain","volume":"155","author":"Gimbel","year":"2014","journal-title":"Pain"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1097\/j.pain.0000000000001928","article-title":"Tanezumab for chronic low back pain: A randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety","volume":"161","author":"Markman","year":"2020","journal-title":"Pain"},{"key":"ref_100","first-page":"523","article-title":"Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: Results of a proof-of-concept study","volume":"7","author":"Tiseo","year":"2014","journal-title":"J. Pain Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.2147\/JIR.S276986","article-title":"Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases","volume":"14","author":"Anyfanti","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"402","DOI":"10.31138\/mjr.310824.cri","article-title":"Cardiovascular Risk in Rheumatoid Arthritis: Considerations on Assessment and Management","volume":"35","author":"Anyfanti","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.31138\/mjr.311023.sji","article-title":"Selective JAK-Inhibitors in Spondyloarthritis","volume":"35","author":"Vassilakis","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13075-024-03354-1","article-title":"Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6\/JAK\/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons","volume":"26","author":"Makabe","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"106347","DOI":"10.1016\/j.phrs.2022.106347","article-title":"Discovery of novel targets in a complex regional pain syndrome mouse model by transcriptomics: TNF and JAK-STAT pathways","volume":"182","author":"Pohoczky","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/1744666X.2024.2400294","article-title":"Nociplastic pain in axial spondyloarthritis and psoriatic arthritis: Role of JAK kinases in immunopathology and therapeutic impact of JAK inhibitors","volume":"21","author":"Horbal","year":"2025","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"129","DOI":"10.31138\/mjr.34.2.129","article-title":"JAK Inhibitors for the Treatment of Axial Spondyloarthritis","volume":"34","author":"Klavdianou","year":"2023","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"104392","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1002\/jsp2.1345","article-title":"Biomolecular therapies for chronic discogenic low back pain: A narrative review","volume":"7","author":"Creemers","year":"2024","journal-title":"JOR Spine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2240894","DOI":"10.1155\/2022\/2240894","article-title":"Hydroxytyrosol Ameliorates Intervertebral Disc Degeneration and Neuropathic Pain by Reducing Oxidative Stress and Inflammation","volume":"2022","author":"Yu","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ebiom.2019.04.032","article-title":"Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model","volume":"43","author":"Krock","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"557","DOI":"10.31138\/mjr.240724.oha","article-title":"Oral Hyaluronic Acid in Osteoarthritis and Low Back Pain: A Systematic Review","volume":"35","author":"Davidson","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbi.2025.03.029","article-title":"Inhibition of TrkB-BDNF positive feedback loop attenuates intervertebral disc degeneration and low back pain in a composite mouse model","volume":"128","author":"Ao","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e1300","DOI":"10.1097\/PR9.0000000000001300","article-title":"Persistent pain signaling and stress response in a mouse model of inflammatory low back pain","volume":"10","author":"Motohashi","year":"2025","journal-title":"Pain. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ecco-jcc\/jjz017","article-title":"Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients with Inflammatory Bowel Disease","volume":"13","author":"Wang","year":"2019","journal-title":"J. Crohn\u2019s Colitis"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1612\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:55:37Z","timestamp":1761533737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/11\/1612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":115,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ph18111612"],"URL":"https:\/\/doi.org\/10.3390\/ph18111612","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}